摘要
目的探讨血浆EB病毒(EBV)DNA拷贝数监测在EBV阳性非霍奇金淋巴瘤化疗疗效评估中的临床应用效果。方法选取2017年5月—2018年7月在我院进行治疗的EBV阳性非霍奇金淋巴瘤患者40例,所有患者均接受2周期的静脉化疗,每进行1个周期后,所有患者抽取外周静脉血以检测EBV-DNA载量,同时结合影像学检查对疗效进行评估。结果40例EBV阳性非霍奇金淋巴瘤患者经2个周期的静脉化疗治疗后,完全缓解(CR)8例,部分缓解(PR)12例,稳定(SD)7例,疾病进展(PD)13例,总有效率为67.50%;化疗有效患者EBV-DNA拷贝数平均为(2435.16±48.72)copies/mL,化疗无效组患者的EBV-DNA拷贝数平均为(41082.91±1021.47)copies/mL,差异有统计学意义(P>0.05)。结论EBV-DNA拷贝数变化可作为化疗疗效判断与预后的有效辅助指标,能够为EBV阳性非霍奇金淋巴瘤患者的临床化疗方案制定及选择提供可靠的依据。
Objective To investigate the clinical effect of EBV DNA copy number monitoring in the evaluation of chemotherapy efficacy of EBV positive non Hodgkin's lymphoma.Methods From May 2017 to July 2018,40 patients with EBV positive non Hodgkin's lymphoma were selected.All patients received two cycles of intravenous chemotherapy.After each cycle,peripheral venous blood was drawn from all patients to detect EBV-DNA load.At the same time,combined with imaging examination,the efficacy was evaluated.Results in this study,after two cycles of intravenous chemotherapy,8 cases of complete remission(CR),12 cases of partial remission(PR),7 cases of stable(SD),13 cases of disease progression(PD),the total effective rate was 67.50%.The median of EBV-DNA copy number in the effective chemotherapy patients was(2435.16±48.72)copies/ml,and the number of EBV-DNA copies in the ineffective chemotherapy group was(2435.16±48.72)copies/mL.The median was(41082.91±1021.47)copies/ml,the difference was statistically significant(P>0.05).Conclusion the change of EBV-DNA copy number can be used as an effective auxiliary index for the evaluation of chemotherapy effect and prognosis,and can provide a reliable basis for the formulation and selection of clinical chemotherapy plan for EBV positive non-Hodgkin's lymphoma patients.
作者
李玲
周瑜
李洁
Li Ling;Zhou Yu;Li Jie(The Second People's Hospital of Pingxiang City,Pingxiang,Jiangxi 337000)
出处
《基层医学论坛》
2020年第8期1037-1039,共3页
The Medical Forum
基金
江西省萍乡市科技基金项目。
关键词
非霍奇金淋巴瘤
EBV阳性
化疗
EB病毒拷贝数监测
疗效评估
Non Hodgkin's lymphoma
EB virus
Chemotherapy Epstein-barr virus copy number monitoring
Therapeutic effect evaluation
